Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Morita A, Ichihara E, Inoue K, Fujiwara K, Yokoyama T, Harada D, Ando C, Kano H, Oda N, Tamura T, Ochi N, Kawai H, Inoue M, Hara N, Fujimoto N, Ichikawa H, Oze I, Hotta K, Maeda Y, Kiura K. Morita A, et al. Among authors: inoue m, inoue k. Int J Cancer. 2024 May 1;154(9):1607-1615. doi: 10.1002/ijc.34842. Epub 2024 Jan 9. Int J Cancer. 2024. PMID: 38196128
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Ichihara E, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ichihara E, et al. Among authors: inoue k. Cancer Immunol Immunother. 2021 Jan;70(1):101-106. doi: 10.1007/s00262-020-02662-0. Epub 2020 Jul 10. Cancer Immunol Immunother. 2021. PMID: 32648165 Free PMC article.
Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Hara N, Ichihara E, Harada D, Inoue K, Fujiwara K, Hosokawa S, Kishino D, Haruyuki K, Ochi N, Oda N, Hotta K, Maeda Y, Kiura K. Hara N, et al. Among authors: inoue k. J Cancer Res Clin Oncol. 2021 Dec;147(12):3749-3755. doi: 10.1007/s00432-021-03615-5. Epub 2021 Mar 29. J Cancer Res Clin Oncol. 2021. PMID: 33779840
Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression.
Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ochi N, et al. Among authors: inoue k. Eur J Cancer. 2021 Nov;157:523-524. doi: 10.1016/j.ejca.2021.07.044. Epub 2021 Sep 1. Eur J Cancer. 2021. PMID: 34479780 No abstract available.
More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance.
Ando C, Ichihara E, Yokoyama T, Inoue K, Tamura T, Fujiwara K, Oda N, Kano H, Kishino D, Watanabe K, Inoue M, Ochi N, Onishi F, Ichikawa H, Kobe H, Tachibana S, Hotta K, Maeda Y, Kiura K. Ando C, et al. Among authors: inoue m, inoue k. J Cancer Res Clin Oncol. 2023 Jul;149(8):4933-4938. doi: 10.1007/s00432-022-04415-1. Epub 2022 Oct 29. J Cancer Res Clin Oncol. 2023. PMID: 36308525
The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study.
Nishimura T, Ichihara E, Yokoyama T, Inoue K, Tamura T, Sato K, Oda N, Kano H, Kishino D, Kawai H, Inoue M, Ochi N, Fujimoto N, Ichikawa H, Ando C, Hotta K, Maeda Y, Kiura K. Nishimura T, et al. Among authors: inoue m, inoue k. Cancers (Basel). 2022 Dec 14;14(24):6184. doi: 10.3390/cancers14246184. Cancers (Basel). 2022. PMID: 36551668 Free PMC article.
9,840 results